Pyxis Oncology
Boston
About Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $224.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: nasdaq:PYXS
- Website: pyxisoncology.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pyxis-oncology-19086 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.